Research on the Evaluation and Optimization of Investment Efficiency of Listed Companies in the Biomedical Industry
This article discusses the evaluation and optimization strategies of investment efficiency in biomedical companies,establishes an investment efficiency evaluation system for the biomedical industry,and applies the DEA model to evaluate the investment efficiency of 20 listed companies in the biomedical industry from 2018 to 2022.The study has found that the average investment efficiency of biomedical listed companies is between 0.88 and 0.97,indicating a relatively low investment efficiency.The Malmquist index model is used to calculate the dynamic changes in investment efficiency,and it is found that the average change in total factor productivity is 0.99,indicating that the overall investment efficiency of the biomedical industry is needed to be improved.Through further analysis of financial reports,it is found that insufficient research and development expenses are an important reason for slow technological progress.The article proposes suggestions to improve the investment efficiency of the biomedical industry from the aspects of technological progress,production and manufacturing,and operation and management.
investment efficiencyDEA-Malmquist index modelbiopharmaceutical scienceslisted company
万方数据
维普
